Table 5.
Subgroup analysis based on the diabetic and non-diabetic population.
| Subgroup | SHR <1.25 | SHR ≥ 1.25 | Univariate analysis | Multivariate analysisa | ||||
|---|---|---|---|---|---|---|---|---|
| (No. of events/patients) | Odds ratio (95% CI) | P-value* | P for interaction | Odds ratio (95% CI) | P-value* | P for interaction† | ||
| MACCEs | ||||||||
| Non-diabetic | 19/162 | 24/79 | 3.704 (1.873–7.324) | <0.001 | 0.252 | 2.716 (1.281–5.762) | 0.009b | 0.358 |
| Diabetic | 9/46 | 17/54 | 1.889 (0.747–4.776) | 0.179 | ||||
| Deaths | ||||||||
| Non-diabetic | 13/162 | 16/79 | 2.911 (1.323–6.407) | 0.008 | 0.914 | 2.394 (1.040–5.507) | 0.040c | 0.930 |
| Diabetic | 4/46 | 11/54 | 2.686 (0.792–9.106) | 0.113 | ||||
a
Forward stepwise regression method was used in the multivariate logistic analysis.
b
Adjusted for age, gender, cardiac arrest, Killip class, heart rate, systolic blood pressure, S2B, PCI, complete revascularization, LVEF, and NT-proBNP.
c
Adjusted for age, gender, Killip class, heart rate, systolic blood pressure, S2B, PCI, complete revascularization, LVEF, and NT-proBNP.
*
P-value for SHR groups;
†
P-value for interaction of groups with subgroups.
S2B, symptom onset to balloon time; PCI, percutaneous coronary intervention; NT-proBNP, N-terminal pro-B type natriuretic peptide; LVEF, left ventricular ejection fraction; SHR, stress hyperglycemia ratio; CI, confidence incidence.